HAART containing nevirapine — Competitive Intelligence Brief

HAART containing nevirapine (HAART containing nevirapine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-nucleoside reverse transcriptase inhibitor. Area: Infectious Disease.

phase 2 Non-nucleoside reverse transcriptase inhibitor Reverse transcriptase Infectious Disease Small molecule

Target snapshot

HAART containing nevirapine (HAART containing nevirapine) — The HIV Netherlands Australia Thailand Research Collaboration. Non-nucleoside reverse transcriptase inhibitor

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
HAART containing nevirapine TARGET	HAART containing nevirapine	The HIV Netherlands Australia Thailand Research Collaboration	phase 2	Non-nucleoside reverse transcriptase inhibitor	Reverse transcriptase
Switch to DRV/cobicistat + 3TC	Switch to DRV/cobicistat + 3TC	Hospitales Universitarios Virgen del Rocío	marketed	Antiretroviral combination therapy (protease inhibitor + pharmacokinetic booster + nucleoside reverse transcriptase inhibitor)	HIV protease, CYP3A4, HIV reverse transcriptase
Switch to B/F/TAF	Switch to B/F/TAF	University of Nairobi	marketed	Antiretroviral combination (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
Nevirapine (Viramune)	Nevirapine (Viramune)	Germans Trias i Pujol Hospital	marketed	Non-nucleoside reverse transcriptase inhibitor (NNRTI)	HIV reverse transcriptase
Reyataz + Norvir + Truvada	Reyataz + Norvir + Truvada	ViiV Healthcare	marketed	Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase
bictegravir/emtricitabine/tenofovir alafenamide	bictegravir/emtricitabine/tenofovir alafenamide	Midland Research Group, Inc.	marketed	Antiretroviral combination (integrase inhibitor + nucleoside reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
Efavirenz (EFV)	Efavirenz (EFV)	Janssen-Cilag S.p.A.	marketed	Non-nucleoside reverse transcriptase inhibitor (NNRTI)	HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Non-nucleoside reverse transcriptase inhibitor class)

1. Laboratoires NEGMA · 2 drugs in this class
2. IRCCS Eugenio Medea · 1 drug in this class
3. Merck Sharp & Dohme LLC · 1 drug in this class
4. The HIV Netherlands Australia Thailand Research Collaboration · 1 drug in this class